Researchers found 41 inaccurate statements on 18 websites, 5.2% of total analyzed web pages. Despite quality criteria, no combination could differentiate accurate from inaccurate content.
Researchers at MD Anderson Cancer Center report a new kidney cancer drug that targets the FLT3-ITD mutation in AML, reducing leukemia cells by 90% in patients. The drug has shown minimal side effects and is being tested in combination with chemotherapy.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a new scoring system that identifies Myelodysplastic Syndrome (MDS) patients with low-risk disease but poor prospects of survival. The system, applied to 856 patients treated between 1976 and 2005, found that older age, low platelet counts, anemia, and p...
The team led by Maria Schumacher, Ph.D., produced clear 3-D images of the structure resulting from two proteins connecting with a DNA site to 'segregate' DNA during cell division. The solved structure provides fundamental insight into how cells divide with intact DNA.
A definitive study of 15 randomized trials found that high-dose chemotherapy and autologous stem cell transplantation had no overall survival benefit for women with node-positive breast cancer. However, there was a slight benefit in relapse-free survival.
Researchers at University of Texas M.D. Anderson Cancer Center report promising early results for bosutinib in patients with chronic myelogenous leukemia (CML) who have developed resistance to frontline therapy. The drug has shown good efficacy and low toxicity, particularly when compared to other tyrosine kinase inhibitors.
Researchers at the University of Texas M. D. Anderson Cancer Center report that a milder chemotherapy regimen before stem cell transplant resulted in complete remission for 45 of 47 patients with relapsed follicular lymphoma. Long-term follow-up showed improved overall survival and progression-free survival rates.
A Phase III clinical trial shows that patients with relapsed CLL who achieve complete response with oblimersen combination therapy live significantly longer than those treated with chemotherapy alone. The median survival time for oblimersen-treated patients is estimated to exceed 49 months, whereas it was 35 months for those on F/C alone.
A peptide vaccine for leukemia improved event-free survival by 8.7 months compared to non-responders, with 36% of responders experiencing complete cytogenetic remission. The vaccine targets cancer cells and induces a specific immune response in patients with HLA-A2
Two drugs, dasatinib and nilotinib, are showing promising results as frontline therapy for newly diagnosed CML patients with high complete cytogenetic response rates of approximately 90% at 6 months. The treatments target a greater variety of genetic variations than imatinib, which has increased the 5-year survival rate for CML patient...
Researchers at M.D. Anderson Cancer Center link diet and gardening to lung cancer risk reduction, finding that smokers and nonsmokers can reduce their risk by eating four or more servings of green salad a week and working in the garden once or twice a week.
A new aerosol launches an immune response in the lungs to wipe out lethal infections, including bacterial and fungal infections. The treatment showed an 83% survival rate against pneumococcal pneumonia in mice treated with the aerosol before exposure.
The study found that lenalidomide-dexamethasone combination therapy slows multiple myeloma disease progression and improves overall survival for patients. The treatment resulted in a median time to disease progression of 11.1 months compared to 4.7 months in the placebo group.
Researchers at M. D. Anderson Cancer Center have identified a tumor-suppressor gene that suppresses lung tumors in mice and could provide new approaches for lung cancer prevention, diagnosis, and treatment. The GPRC5A gene is under-expressed in human lung cancer cells and its expression was found to be lower in 61% of human non-small c...
Researchers at the University of Texas M. D. Anderson Cancer Center and Rice University have successfully destroyed liver cancer tumors using radio waves that heat up carbon nanotubes embedded in them. While there were some side effects on healthy tissue, the study shows promise for a new therapy.
A team of researchers found that SENP1 regulates the entire hypoxic response and plays a role in other kinds of cancers. Inhibiting SENP1 might be one way to turn off tumor growth by cutting off a protein's ability to build new blood vessels.
A human peptide called LL37, normally used as a natural antibiotic, can bind to the body's own DNA and trigger an immune response. This may drive autoimmunity in psoriasis and other autoimmune diseases.
Researchers have developed a customized virus, Delta-24-RGD, that targets and eliminates brain tumor stem cells. In lab experiments and human brain cancer in mice, the virus shows promise in killing glioblastoma multiforme tumors, which are resistant to radiation and chemotherapy.
Researchers at the University of Texas M. D. Anderson Cancer Center found that congestive heart failure is rare among leukemia patients taking imatinib. Only 22 out of 1,276 patients developed symptoms that could be caused by heart failure, and most had underlying medical conditions that also contributed to their condition.
A study by researchers at the University of Texas M.D. Anderson Cancer Center has identified a link between inflammatory protein Tumor Necrosis Factor alpha (TNFa) and breast cancer, highlighting a new pathway for potential clinical interventions. The research found that TNFa activates an enzyme that inactivates tumor-suppressing genes...
A connection between DNA damage control and chromatin remodeling has been discovered, opening new avenues for cancer treatment. The study reveals that phosphorylation of a chromatin remodeling complex regulates checkpoint pathways but not DNA repair pathways.
Researchers at the University of Texas M.D. Anderson Cancer Center discovered that a protein called IKK-alpha protects an important cell defense mechanism from silencing in skin cancers. The protein prevents DNA methylation, which normally silences the checkpoint gene 14-3-3-sigma.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a gene therapy that selectively targets and eliminates pancreatic cancer cells, inhibiting metastasis and prolonging survival with minimal toxicity. The therapy, called VISA-BikDD, has shown significant promise in preclinical trials, with treated mice su...
Researchers at M. D. Anderson Cancer Center have identified a new oncogene, insulin-like growth factor binding protein 2 (IGFBP2), that contributes to the formation of two types of brain malignancies, astrocytoma and oligodendroglioma.
A study of 132 rare ovarian cancer survivors found that most retained menstrual function and reproductive ability after treatment. Despite reproductive concerns, survivors were more likely to be in meaningful, positive relationships than healthy counterparts.
Researchers found a widening disparity in life expectancy between white and black women with advanced breast cancer, with median survival rates differing by up to 8.8% over the last two decades. Socio-economic factors, such as access to healthcare and treatment options, are suspected to be contributing factors.
A large Phase III study found that shark cartilage extract AE-941 has no benefit when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer. The study did not meet its primary endpoint: survival, and the researchers cast major skepticism on the efficacy of shark cartilage products.
A Phase II clinical trial at M.D. Anderson Cancer Center found dasatinib achieves complete cytogenetic response in 77-95% of newly diagnosed CML patients, compared to historical data on imatinib. The rapid response rate suggests dasatinib may be more effective as a first-line treatment for CML.
Researchers at University of Texas M. D. Anderson Cancer Center developed a lung cancer risk assessment tool using standard clinical and epidemiological data. The model assigns a score assessing a person's risk for the disease, with a prediction level of about 60 percent.
Researchers have found that the novel targeted therapy NPI-0052 effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins. This approach has shown greater efficacy than its predecessor bortezomib when combined with other agents.
Researchers found a strong association between HRT use and decreased breast cancer incidence, with a 6.7% decline between 2002 and 2003. The lowest rate seen since about 1987 was maintained in 2004, primarily in estrogen-receptor-positive cancers.
Researchers at the University of Texas M. D. Anderson Cancer Center have successfully delivered a cancer-suppressing gene into tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle. The gene, FUS1, was found to be active in metastatic non-small cell lung cancer tumors.
Researchers found that Hodgkin's disease survivors with higher chromosomal aberrations are two-and-a-half times more likely to develop another type of cancer. Chromosomal breaks, particularly those on one chromosome arm, may serve as a biomarker for predicting second primary tumor risk.
A protein called tissue transglutaminase (TG2) protects human pancreatic cancer cells from autophagy, a form of programmed cell death, researchers found. Inhibiting TG2 led to a drastic reduction in its expression and telltale signs of autophagy in the cancer cells.
A study of 17 studies from nine countries found that removing and examining more lymph nodes during colon cancer surgery improves patient outcomes. The research suggests that knowing how far a cancer has spread leads to tailored treatment, ultimately resulting in better survival rates for patients.
A phase III clinical trial found that the first antisense drug, oblimersen, improved response rates in CLL patients who remained sensitive to chemotherapy drug fludarabine. The study showed a four-fold increase in 'CR/nPR' in these patients compared to those no longer responding to fludarabine.
Researchers have developed a new genomic microarray test that accurately identifies the ER and HER-2 status of breast tumors, which can inform personalized treatment planning. The test showed 90% accuracy for both receptors, comparable to existing pathology tests.
Researchers developed a simple and accurate two-gene test that distinguishes between gastrointestinal stromal tumor (GIST) and leiomyosarcoma (LMS) with near perfect accuracy. The Top Scoring Pair analysis approach has potential for wider application in individualized diagnosis and treatment of other types of cancer.
Researchers at University of Texas M. D. Anderson Cancer Center found that aspirin significantly improves survival rates among cancer patients with low platelet counts who experience heart attacks, even when taking anticoagulants. Aspirin also showed benefits for patients with normal platelet counts.
A study at the University of Texas M.D. Anderson Cancer Center found that combining cromolyn with chemotherapy reduced pancreatic tumor growth by 85% compared to control animals. The combination also increased the effectiveness of standard chemotherapy.
A new analysis suggests that the decline in breast cancer incidence between 2002 and 2003 was largely due to the reduction of hormone replacement therapy (HRT) use. The study found a 7% relative decline in breast cancer cases, with an absolute decline of about 14,000 fewer women diagnosed in 2003 compared to 2002.
A Phase II trial found that 86% of patients with inflammatory breast cancer responded to lapatinib-chemotherapy, offering new hope for treatment. The study also showed that 25-30% of patients responded within two weeks of treatment alone.
Researchers developed genomic tests to predict breast cancer response to chemotherapy and hormonal therapy, with promising results in clinical trials. The tests showed high accuracy in predicting treatment response and patient outcomes, offering new hope for personalized treatment planning.
Researchers at M.D. Anderson Cancer Center report clinical activity of MK-0457 against T315I BCR-ABL mutation in CML and ALL, and JAK-2 mutation in myeloproliferative disorders. The drug shows minimal side effects and has potential to benefit patients with these rare and aggressive cancers.
Researchers have found that the experimental drug ABT-737 can destroy AML blast, progenitor and stem cells, potentially providing a new way to treat cancer. Combining ABT-737 with another agent may overcome resistance and improve treatment outcomes.
Researchers discovered a novel 'Trojan Horse' agent, VEGF121/rGel, that completely prevented bone tumor development in 50% of mice. The agent stops specialized cells within the bone from chewing up bone material to make room for implanted tumors to grow.
African-American women with breast cancer had lower survival rates and larger, later-stage tumors compared to Hispanic and Caucasian women. Research suggests intrinsic biological differences in the disease contribute to these disparities.
Acute myelogenous leukemia (AML) patients who have multiple active molecular pathways in their blood and bone marrow samples tend to have a poorer prognosis. Targeting just one pathway is unlikely to be effective due to cross-activation, requiring the development of multi-drug therapies.
Researchers found that a defective version of the NPRL2 tumor suppressor gene makes lung cancer cells resistant to cisplatin, a common chemotherapy drug. Gene therapy targeting this gene may restore sensitivity to cisplatin, offering new hope for treating resistant lung cancer.
Researchers at the University of Texas M.D. Anderson Cancer Center have identified a new molecular pathway that helps breast cancer cells survive. The pathway involves estrogen, BCA3 protein, and SIRT1, and has potential as a target for chemotherapy enhancement.